Who will benefit from treatment against EGFR?
Arribas
Joaquín
J
Baselga
José
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D009154:Mutation; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases